ClinicalTrials.gg
TerminatedNCT00666497Updated May 8, 2015

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 2 interventional study of Azacitidine and MGCD0103 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), sponsored by Mirati Therapeutics Inc.. Terminated at 8 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
192nd of 211
6 · median 50
Started
2008
with 6 others
Phase 2
105 of 214
40 open now
Registered
13th of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 192nd largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2008, is one of 105 in phase 2, and was the 13th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.

Read the detailed description

This randomized, 3-arm Phase 2 study will compare the safety and efficacy of single-agent azacitidine (currently 1 of 3 approved treatments for myelodysplastic syndrome [MDS]) to that of single-agent MGCD0103 and to that of combination therapy with MGCD0103 and azacitidine in elderly patients with acute myelogenous leukemia (AML) or intermediate-2 (Int-2) or high-risk MDS, for whom no standard of care exists. The goal of the study is to determine which of the 3 treatment arms are worthy of further investigation in a subsequent Phase 3 study of elderly subjects with AML or Int-2 or high-risk MDS.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)

Keywords

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Azacitidine
  • Vidaza
  • MGCD0103
  • Histone deacetylase inhibitor
  • DNA methyltransferase inhibitor
  • Epigenetic Therapy
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written , and be willing and able to comply with all the study procedures
  • Must be 60 years of age or older
  • Must have a pathologic confirmation of newly diagnosed (de novo or untreated secondary) AML or newly diagnosed Int-2 or high-risk MDS (IPSS classification) according to WHO criteria
  • Must have a (ECOG) performance status of 0, 1, or 2
  • Must have adequate organ function, including total ≤ 1.5 x (ULN); \& ALT ≤ 2.5 x ULN; and serum creatinine ≤ 2.0 x ULN.

Exclusion criteria

Exclusion Criteria:

  • Considered fit for intensive chemotherapy and opt to be treated with intensive chemotherapy
  • Prior transplantation or any prior anticancer therapy (standard or , including chemotherapy, treatment with HDAC inhibitors, or combination HDAC and azacitidine) administered to treat AML or MDS.
  • Clinical evidence of central nervous system (CNS) involvement by leukemia
  • A diagnosis of promyelocytic leukemia
  • Previous or concurrent except adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least 3 years prior to study entry
  • Active and uncontrolled infection
  • Known positive serology for surface antigen (HBsAg), antibody (HCV Ab) or (HIV)
  • Less than 4 weeks elapsed since any major surgery
  • Any prior or active disease that may interfere with the procedures or evaluations to be conducted in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    A

    Azacitidine

    Drug: Azacitidine

  • Experimental
    B

    MGCD0103

    Drug: MGCD0103

  • Experimental
    C

    Azacitidine + MGCD0103

    Drug: Azacitidine · Drug: MGCD0103

Interventions

  • 75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle

    Also known as: Vidaza

  • 90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle

  • 90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle

06

What researchers measure

Primary outcomes

  1. Overall response rate as assessed using IWG criteria for AML and MDS

    Time frame: After 45, 90, 135, and 180 subjects are enrolled and evaluated for response to treatment

Secondary outcomes

  1. Duration of response; Time to progression; Progression-free survival; RBC transfusion independence; Hematologic improvement; Quality of life; Safety profile; and Pharmacokinetics of azacitidine and MGCD0103

    Time frame: After 45, 90, 135, and 180 subjects are enrolled and evaluated for response to treatment

07

Study locations

8 sites
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Diamond Centre, Leukemia/BMT Program of BC
    Vancouver, British Columbia V5Z 4E3, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • University Hospital
    Birmingham, B15 2TH, United Kingdom
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • St. Bartholomews Hospital
    London, EC1A 7BE, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
Start
Jun 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results delay requested
Apr 6, 2015
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00666497
Responsible party
Sponsor
First posted
Apr 25, 2008
Start date
Jun 2008
Primary completion
Apr 2009
Completion
Apr 2009
Last update
May 8, 2015

Study contacts

Gregory Reid, MSc, MBA
study director · MethylGene Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Mocetinostat

Start the discussion